• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

MS highlights from EAN 2019

July 10, 2019  

HSCT vs. drug in RRMS: head-to-head study

June 19, 2019  

Switching therapies in MS – what is the evidence?

May 28, 2019  

AAN 2019 DAILY REPORT

May 9, 2019  

Europe restricts alemtuzumab use for MS

May 1, 2019  

Secondary-progressive MS: conceptual and practical challenges

April 17, 2019  

Siponimod receives FDA approval for SPMS

March 29, 2019  

Polypharmacy common in MS patients

March 13, 2019  

Benefits to early switching in MS: MSBase analysis

February 27, 2019  

Phase III trials in neurology – 2018 in review

January 24, 2019  
Previous
22
23
24
25
26
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Management of refractory epilepsy: highlights from ILAE 2025 posted on October 29, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions